My Blue Dots

FOSTER CITY, Calif. & BALLERUP, Denmark–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases. STAT6 is the specific transcription factor required for IL-4 and IL-13 cytokine signaling, which are clinically validated tar

HUNT VALLEY, Md.–(BUSINESS WIRE)–Omega Healthcare Investors, Inc. (NYSE:OHI) announced today that it is scheduled to release its earnings results for the quarter ended December 31, 2024, on Wednesday, February 5, 2025, after market close. In conjunction with its release, Omega will be conducting a conference call on Thursday, February 6, 2025, at 10 a.m. Eastern Time to review its 2024 fourth quarter results and current developments. To listen to the conference call via webcast, log on to www

ST. PAUL, Minn.–(BUSINESS WIRE)–Ecolab will host a live webcast to discuss its 2024 fourth quarter results. A news release containing fourth quarter results is expected to be issued before market open on February 11, 2025. Details for the public webcast are as follows: TIME: 1:00 p.m. Eastern Time DATE: Tuesday, February 11, 2025 DURATION: One hour LOCATION: www.ecolab.com/investor ARCHIVE: A replay of the webcast and supplemental data will be available on Ecolab’s website. About Ecolab A tru

DALLAS–(BUSINESS WIRE)–AIC, a division of AIS Healthcare, now offers ALYGLO™, manufactured by GC Biopharma, for the treatment of patients with primary humoral immunodeficiency (PI) in adults. This includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID). The nationally accredited home infusion teams at AIC collaborate c

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy. The Food and Drug Administration (FDA) grants Priority Review to